Drug Trial Radar · NCT01042379
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Mar 1, 2010
Primary completion
Dec 2030
Study completion Dec 2031
Sponsor
- Lead sponsor
- QuantumLeap Healthcare CollaborativeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Conditions
- Breast Neoplasms
- Breast Cancer
- Breast Tumors
- Angiosarcoma
- TNBC - Triple-Negative Breast Cancer
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- Hormone Receptor Positive Tumor
- Hormone Receptor Negative Tumor
- Early-stage Breast Cancer
- Locally Advanced Breast Cancer
Interventions
Standard TherapyDrug
Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
AMG 386 with or without TrastuzumabDrug
Arm is closed.
AMG 479 (Ganitumab) plus MetforminDrug
Arm is closed.
MK-2206 with or without TrastuzumabDrug
Arm is closed.
AMG 386 and TrastuzumabDrug
Arm is closed.
T-DM1 and PertuzumabDrug
Arm is closed.
Pertuzumab and TrastuzumabDrug
Arm is closed for Accrual. Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
GanetespibDrug
Arm is closed.
ABT-888Drug
Arm is closed.
NeratinibDrug
Arm is closed.
PLX3397Drug
Arm is closed.
Pembrolizumab - 4 cycleDrug
Arm is closed.
Talazoparib plus IrinotecanDrug
Arm is closed.
Patritumab and TrastuzumabDrug
Arm is closed.
Pembrolizumab - 8 cycleDrug
Arm is closed.
SGN-LIV1ADrug
Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
Durvalumab plus OlaparibDrug
Arm is closed.
SD-101 + PembrolizumabDrug
Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Tucatinib plus trastuzumab and pertuzumabDrug
Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
CemiplimabDrug
Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Cemiplimab plus REGN3767Drug
Arm is closed. Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Trilaciclib with or without trastuzumab + pertuzumabDrug
Arm closed for accrual. Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles For HER2+: Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
SYD985 ([vic-]trastuzumab duocarmazine)Drug
Arm is closed. SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug
Arm is closed. For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug
Arm is closed. For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle
AmcenestrantDrug
Arm is closed. Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks.
Amcenestrant + AbemaciclibDrug
Arm is closed. Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
Amcenestrant + LetrozoleDrug
Arm is closed. Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
ARX788Drug
Arm is closed. ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
ARX788 + CemiplimabDrug
Arm is closed. ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
VV1 + CemiplimabDrug
Arm is closed. VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
Datopotamab deruxtecanDrug
Arm is closed. Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
Datopotamab deruxtecan + DurvalumabDrug
Arm is closed. Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
ZanidatamabDrug
Zanidatamab: IV Infusion at a 2-tiered flat dose. 1,800mg (\<70 kg) and 2400mg (≥70 kg). Neoadjuvant doing of zanidatamab: The initial dose will be administered on Cycle 1 Day 1, with Cycle 2 Day 1 occurring 14 days thereafter, followed by subsequent dosing every 3 weeks (Q3W) for a total of up to 5 doses in block A, up to 4 doses Block B, up to 5 doses Block C. Adjuvant dosing of zanidatamab: Administered every 3 weeks (Q3W) for a total of 1 year of HER2 based therapy. The total number of adjuvant weeks will be dependent on the number of weeks of exposure of zanidatamab in Blocks A, B, and C.
LasofoxifeneDrug
Arm is closed. Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
Z-endoxifenDrug
Arm is closed. Z-endoxifen: 10 mg QD, p.o., for 24 weeks
ARV-471Drug
Arm is closed. ARV-471: 200 mg QD, p.o, for 24 weeks.
ARV-471 + LetrozoleDrug
Arm is closed. ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
ARV-471 + AbemaciclibDrug
Arm is closed. ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
Endoxifen + AbemaciclibDrug
Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
Rilvegostomig + TDXdDrug
Arm closed to accrual Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
Dan222 + NiraparibDrug
Arm is closed. DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
Sarilumab + Cemiplimab + PaclitaxelDrug
Arm is closed to accrual. Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
GSK 5733584Drug
Arm is open for accrual. Route: Intravenous infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection. Will receive a max of 12 weeks.
GSK 5733584 + DostarlimabDrug
Arm is open for accrual. GSK 5733584 Route: Intravenous Infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection x 12 weeks max. Dostarlimab Route: Intravenous Infusion Dosage Form: 500 mg fixed dose intravenous Q3W for infusion x 12 weeks max.
Ivonescimab (20mg/kg Q3W)Drug
Strengths to be used in trial: 1. 20 mg/kg IV Q3W monotherapy 2. 20 mg/kg IV Q3W with paclitaxel 3. 20 mg/kg IV Q3W with carboplatin and paclitaxel. Standard Regimen: 20 mg/kg IV Q3W. Patients in Block A will receive a minimum of 6 weeks a maximum of 12 weeks of Ivonescimab monotherapy in Block A. Patients that have completed Block A, may receive ivonescimab plus paclitaxel or ivonescimab plus paclitaxel plus carboplatin in Block B (depending on subtype).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.Time frame: Post surgery based on upto 36-week treatment
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Mayo Clinic - Scottsdale
Scottsdale, Arizona · Not yet recruiting
University of Arizona
Tucson, Arizona · Active not recruiting
University of California - Davis, Comprehensive Cancer Center
Davis, California · Recruiting
City of Hope
Duarte, California · Recruiting
University of California San Diego
La Jolla, California · Recruiting
University of Southern California
Los Angeles, California · Recruiting
HOAG Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
University of California San Francisco (UCSF)
San Francisco, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Loyola University
Maywood, Illinois · Recruiting
University of Kansas
Westwood, Kansas · Active not recruiting
Herbert-Herman Cancer Center, Sparrow Hospital
Lansing, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center
Saint Louis Park, Minnesota · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center / NYU Langone Health
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
University of Rochester Wilmot Cancer Institute
Rochester, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University, Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio · Recruiting
Oregon Health & Science Institute (OHSU)
Portland, Oregon · Recruiting
University of Pennsylvania (U Penn)
Philadelphia, Pennsylvania · Recruiting
University Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Active not recruiting
Sanford Clinical Research
Sioux Falls, South Dakota · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Active not recruiting
University of Texas, Southwestern Medical Center
Dallas, Texas · Active not recruiting
University of Texas, M.D. Anderson Cancer Center
Houston, Texas · Active not recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Inova Health System
Falls Church, Virginia · Active not recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.